Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Human Genetics, |
RCV000659988 | SCV000781909 | likely pathogenic | Neurofibromatosis, type 1 | 2016-11-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005019097 | SCV005646691 | pathogenic | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2024-06-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000659988 | SCV005754528 | pathogenic | Neurofibromatosis, type 1 | 2024-05-12 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Val497Glyfs*3) in the NF1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with NF1-related conditions. ClinVar contains an entry for this variant (Variation ID: 547591). For these reasons, this variant has been classified as Pathogenic. |